The transcriptional factors HIF-1 and HIF-2 and their novel inhibitors in cancer therapy N Albadari, S Deng, W Li Expert opinion on drug discovery 14 (7), 667-682, 2019 | 256 | 2019 |
Current advances of tubulin inhibitors as dual acting small molecules for cancer therapy KE Arnst, S Banerjee, H Chen, S Deng, DJ Hwang, W Li, DD Miller Medicinal research reviews 39 (4), 1398-1426, 2019 | 116 | 2019 |
Heterocyclic-fused pyrimidines as novel tubulin polymerization inhibitors targeting the colchicine binding site: structural basis and antitumor efficacy S Banerjee, KE Arnst, Y Wang, G Kumar, S Deng, L Yang, G Li, J Yang, ... Journal of medicinal chemistry 61 (4), 1704-1718, 2018 | 96 | 2018 |
Structure–activity relationship study of novel 6-aryl-2-benzoyl-pyridines as tubulin polymerization inhibitors with potent antiproliferative properties H Chen, S Deng, Y Wang, N Albadari, G Kumar, D Ma, W Li, SW White, ... Journal of Medicinal Chemistry 63 (2), 827-846, 2019 | 39 | 2019 |
Design, synthesis, and biological evaluation of stable colchicine-binding site tubulin inhibitors 6-aryl-2-benzoyl-pyridines as potential anticancer agents H Chen, S Deng, N Albadari, MK Yun, S Zhang, Y Li, D Ma, DN Parke, ... Journal of medicinal chemistry 64 (16), 12049-12074, 2021 | 34 | 2021 |
An orally available tubulin inhibitor, VERU-111, suppresses triple-negative breast cancer tumor growth and metastasis and bypasses taxane resistance S Deng, RI Krutilina, Q Wang, Z Lin, DN Parke, HC Playa, H Chen, ... Molecular cancer therapeutics 19 (2), 348-363, 2020 | 28 | 2020 |
Orally available tubulin inhibitor VERU-111 enhances antitumor efficacy in paclitaxel-resistant lung cancer F Mahmud, S Deng, H Chen, DD Miller, W Li Cancer letters 495, 76-88, 2020 | 22 | 2020 |
Repression of intestinal transporters and FXR-FGF15 signaling explains bile acids dysregulation in experimental colitis-associated colon cancer L Cao, Y Che, T Meng, S Deng, J Zhang, M Zhao, W Xu, D Wang, Z Pu, ... Oncotarget 8 (38), 63665, 2017 | 20 | 2017 |
Cabozantinib for HCC treatment, from clinical back to experimental models S Deng, A Solinas, DF Calvisi Frontiers in oncology 11, 756672, 2021 | 17 | 2021 |
An on-line high-performance liquid chromatography− diode-array detector− multi-stage mass spectrometry− deoxyribonucleic acid− 4′, 6-diamidino-2-phenylindole− fluorescence … S Li, H Jiang, Z Lin, S Deng, Y Guan, H Wang, S Chen Journal of Chromatography A 1424, 37-50, 2015 | 17 | 2015 |
X-ray crystallography-guided design, antitumor efficacy, and QSAR analysis of metabolically stable cyclopenta-pyrimidinyl dihydroquinoxalinone as a potent tubulin … S Banerjee, F Mahmud, S Deng, L Ma, MK Yun, SO Fakayode, KE Arnst, ... Journal of medicinal chemistry 64 (17), 13072-13095, 2021 | 14 | 2021 |
Recent advances in antibody-drug conjugates for breast cancer treatment S Deng, Z Lin, W Li Current Medicinal Chemistry 24 (23), 2505-2527, 2017 | 13 | 2017 |
SB226, an inhibitor of tubulin polymerization, inhibits paclitaxel-resistant melanoma growth and spontaneous metastasis S Deng, S Banerjee, H Chen, S Pochampally, Y Wang, MK Yun, ... Cancer letters 555, 216046, 2023 | 8 | 2023 |
Nanoformulation design and therapeutic potential of a novel tubulin inhibitor in pancreatic cancer RS Bhattarai, V Kumar, S Romanova, J Bariwal, H Chen, S Deng, ... Journal of controlled release 329, 585-597, 2021 | 7 | 2021 |
Discovery of a highly selective and potent TRPC3 inhibitor with high metabolic stability and low toxicity S Zhang, LO Romero, S Deng, J Wang, Y Li, L Yang, DJ Hamilton, ... ACS Medicinal Chemistry Letters 12 (4), 572-578, 2021 | 6 | 2021 |
Molecular modelling guided design, synthesis and QSAR analysis of new small molecule non-lipid autotaxin inhibitors S Banerjee, DD Norman, S Deng, SO Fakayode, SC Lee, AL Parrill, W Li, ... Bioorganic chemistry 103, 104188, 2020 | 6 | 2020 |
pH-sensitive nanomedicine of novel tubulin polymerization inhibitor for lung metastatic melanoma RS Bhattarai, J Bariwal, V Kumar, C Hao, S Deng, W Li, RI Mahato Journal of Controlled Release 350, 569-583, 2022 | 5 | 2022 |
Colchicine-binding site agent CH-2-77 as a potent tubulin inhibitor suppressing triple-negative breast cancer S Deng, RI Krutilina, KL Hartman, H Chen, DN Parke, R Wang, F Mahmud, ... Molecular cancer therapeutics 21 (7), 1103-1114, 2022 | 5 | 2022 |
Synthesis and biological evaluation of selective survivin inhibitors derived from the MX-106 hydroxyquinoline scaffold N Albadari, S Deng, H Chen, G Zhao, J Yue, S Zhang, DD Miller, Z Wu, ... European journal of medicinal chemistry 224, 113719, 2021 | 5 | 2021 |
Combination of AFP vaccine and immune checkpoint inhibitors slows hepatocellular carcinoma progression in preclinical models X Lu, S Deng, J Xu, BL Green, H Zhang, G Cui, Y Zhou, Y Zhang, H Xu, ... The Journal of Clinical Investigation 133 (11), 2023 | 2 | 2023 |